Scholarlink

Objective <p>Antibody screening and identification facilitates the issue of antigen-negative blood for patients with alloantibodies to red blood cell (RBC) antigens, thereby maximizing blood safety and the survival of transfused donor cells. The sensitivity and specificity of reagent red blood cells (RRBCs) used in pre-transfusion testing varies between manufacturers. This Phase II study aimed to build on a previously published Phase I study comparing the analytical performance of four manufacturers’ RRBCs in column agglutination technology (CAT). A total of 231 patient samples with a negative indirect antiglobulin test (IAT) results were tested using Immulab, Bio-Rad, Grifols, and QuidelOrtho RRBCs. Phase II results were pooled with Phase I results to provide more accurate calculations of the RRBC analytical performance.</p> Results <p>The sensitivity of the RRBCs used in the combined studies was 94.52% (95%CI 86.56–98.49%) for Bio-Rad, 81.48% (95%CI 71.30–89.25%) for Grifols, and 95.71% (95%CI 87.98–99.11%) for QuidelOrtho RRBCs. The sensitivity of Immulab RRBCs were stratified based on performance in the three CAT platforms: 100%, 95%CI 95.07–100.00% in Bio-Rad CAT, 100%, 95%CI 95.55–100.00% in Grifols CAT and 100%, 95%CI 94.87–100.00% in QuidelOrtho CAT.</p> Conclusions <p>Immulab 0.8% RRBCs showed greater sensitivities and NPVs than the equivalent Bio-Rad, Grifols, and QuidelOrtho RRBCs in Bio-Rad, Grifols, and QuidelOrtho CAT, respectively. These differences may have implications in clinical pre-transfusion settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

New insights into the sensitivity of Immulab reagent red blood cells compared to Bio-Rad, Grifols and QuidelOrtho

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月1日

查看全文
  • Jessica Guglielmino,
  • Fiona J. Morris,
  • Claire M. Grattidge,
  • Denise E. Jackson

摘要

Objective

Antibody screening and identification facilitates the issue of antigen-negative blood for patients with alloantibodies to red blood cell (RBC) antigens, thereby maximizing blood safety and the survival of transfused donor cells. The sensitivity and specificity of reagent red blood cells (RRBCs) used in pre-transfusion testing varies between manufacturers. This Phase II study aimed to build on a previously published Phase I study comparing the analytical performance of four manufacturers’ RRBCs in column agglutination technology (CAT). A total of 231 patient samples with a negative indirect antiglobulin test (IAT) results were tested using Immulab, Bio-Rad, Grifols, and QuidelOrtho RRBCs. Phase II results were pooled with Phase I results to provide more accurate calculations of the RRBC analytical performance.

Results

The sensitivity of the RRBCs used in the combined studies was 94.52% (95%CI 86.56–98.49%) for Bio-Rad, 81.48% (95%CI 71.30–89.25%) for Grifols, and 95.71% (95%CI 87.98–99.11%) for QuidelOrtho RRBCs. The sensitivity of Immulab RRBCs were stratified based on performance in the three CAT platforms: 100%, 95%CI 95.07–100.00% in Bio-Rad CAT, 100%, 95%CI 95.55–100.00% in Grifols CAT and 100%, 95%CI 94.87–100.00% in QuidelOrtho CAT.

Conclusions

Immulab 0.8% RRBCs showed greater sensitivities and NPVs than the equivalent Bio-Rad, Grifols, and QuidelOrtho RRBCs in Bio-Rad, Grifols, and QuidelOrtho CAT, respectively. These differences may have implications in clinical pre-transfusion settings.